New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?

Francesco Passiglia, Antonio Galvano, Daniele Fanale, Marta Castiglia, Giuseppe Bronte, Antonio Russo, Viviana Bazan, Giuseppe Cicero, Marc Peeters, Christian Rolfo, Nicola Silvestris, Antonio Giordano, Antonio Giordano, Christian Diego Rolfo, Giovanni Sortino

Risultato della ricerca: Article

54 Citazioni (Scopus)

Abstract

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.
Lingua originaleEnglish
pagine (da-a)24780-24796
Numero di pagine17
RivistaOncotarget
Volume6
Stato di pubblicazionePublished - 2015

Fingerprint

Colorectal Neoplasms
Mutation
Therapeutics
Monoclonal Antibodies
R Factors
Proxy
Epidermal Growth Factor Receptor
Biomarkers
Biopsy
Drug Therapy
DNA
Genes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? / Passiglia, Francesco; Galvano, Antonio; Fanale, Daniele; Castiglia, Marta; Bronte, Giuseppe; Russo, Antonio; Bazan, Viviana; Cicero, Giuseppe; Peeters, Marc; Rolfo, Christian; Silvestris, Nicola; Giordano, Antonio; Giordano, Antonio; Rolfo, Christian Diego; Sortino, Giovanni.

In: Oncotarget, Vol. 6, 2015, pag. 24780-24796.

Risultato della ricerca: Article

@article{247ac97cb2064335b0d3399d629ca379,
title = "New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?",
abstract = "Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.",
author = "Francesco Passiglia and Antonio Galvano and Daniele Fanale and Marta Castiglia and Giuseppe Bronte and Antonio Russo and Viviana Bazan and Giuseppe Cicero and Marc Peeters and Christian Rolfo and Nicola Silvestris and Antonio Giordano and Antonio Giordano and Rolfo, {Christian Diego} and Giovanni Sortino",
year = "2015",
language = "English",
volume = "6",
pages = "24780--24796",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",

}

TY - JOUR

T1 - New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?

AU - Passiglia, Francesco

AU - Galvano, Antonio

AU - Fanale, Daniele

AU - Castiglia, Marta

AU - Bronte, Giuseppe

AU - Russo, Antonio

AU - Bazan, Viviana

AU - Cicero, Giuseppe

AU - Peeters, Marc

AU - Rolfo, Christian

AU - Silvestris, Nicola

AU - Giordano, Antonio

AU - Giordano, Antonio

AU - Rolfo, Christian Diego

AU - Sortino, Giovanni

PY - 2015

Y1 - 2015

N2 - Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.

AB - Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti- EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.

UR - http://hdl.handle.net/10447/202511

UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=4959&path%5B%5D=11657

M3 - Article

VL - 6

SP - 24780

EP - 24796

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -